By Alice Klein
A vaccine that protects against one of the main common cold viruses has been shown to be safe and effective in a clinical trial and could be available by 2024.
Respiratory syncytial virus (RSV) is so contagious that more than 90 per cent of people have experienced their first infection by the age of 2. It usually causes cold symptoms but can lead to severe illness in young children and older people. Globally, around 60,000 children …
Existing subscribers, please log in with your email address to link your account access.
Paid annually by Credit Card
Inclusive of applicable taxes (VAT)
*Free gift is only available with annual subscription purchases where subscription delivery is in the United Kingdom, USA, Canada, Australia, New Zealand or Euro area